Caricamento...
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
BACKGROUND: Mesenchymal stem cells (MSCs) are considered the best candidate in stem cells therapy due to their multipotent differentiation ability, low expression of co-stimulatory molecules (CD80, CD86, CD34 and HLA-II) and immunosuppression effects on in vivo immune responses. MSCs were now widely...
Salvato in:
| Pubblicato in: | Biol Res |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4363195/ https://ncbi.nlm.nih.gov/pubmed/25654296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/0717-6287-48-6 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|